Notification of Major Interest in Shares

ReGen Therapeutics Plc

2.    Reason for the notification:

An acquisition or disposal of voting rights

3.    Full name of person(s) subject to the notification obligation (iii):

Andrew Clement Wilson

4.    Full name of shareholder(s) (if difference from 3):

As Above

5.    Date of the transaction and date on which the threshold is crossed or reached (v):

30th April 2009

6.    Date on which issued notified:

1st May 2009

7.    Threshold(s) that is/are crossed or reached:

11% to 10%

8.    Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code        GB00B28XMY25

Situation Previous to the triggering transaction (vi) –
Number of Shares                2,600,750
Number of Voting Rights (viii)        2,600,750

Resulting situation after the triggering transaction (viii) –
Number of Shares                2,559,750
Number of Voting Rights – Direct (x)        2,559,750
Number of Voting Rights – Indirect (xi)        N/A
% of voting rights – Direct            10.03%
% of voting rights – Indirect            N/A

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument                N/A

Expiration date (xiii)                N/A

Exercise/Conversion Period/Date (xiv)            N/A

Number of voting rights that may be acquired if the
instrument is exercised/converted            N/A

% of voting rights                    N/A

Total (A+B)

Number of voting rights                    2,559,750

% of voting rights                    10.03%

9.    Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

Proxy Voting:

10.    Name of the proxy holder:                                                      N/A

11.    Number of voting rights proxy holder will cease to hold:                    N/A

12.    Date on which proxy holder will cease to hold voting rights:              N/A

13.    Additional information:                                            Brewin Dolphin As
Broker

14.    Contact name:                                                    Stephen Cartwright

15.    Contact telephone number:                    02890446000

For further information:

For further information, please contact:

Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920